The groundbreaking success of Viagra undeniably reshaped the drug landscape, but investing in companies primarily reliant on unbranded versions presents a uncertain picture. Despite early returns were significant, the end of patents and the rise of cheaper alternatives have weakened market share. Consequently, a thorough analysis of current financi